

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/LD10DF492FDEN.html>

Date: October 2018

Pages: 80

Price: US\$ 3,500.00 (Single User License)

ID: LD10DF492FDEN

Abstracts

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2018

SUMMARY

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 26 molecules. The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2018, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 11 and 3 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Solid Tumor, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Lymphoma, Cervical Cancer, Colon Carcinoma, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Autoimmune Disorders, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Chronic Inflammation, Chronic Lymphocytic Leukemia (CLL),

Colorectal Cancer, Endometrial Cancer, Gliosarcoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Hodgkin Lymphoma, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)

The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects

The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies
Involved in Therapeutics Development

Avacta Life Sciences Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Crescendo Biologics Ltd

Eli Lilly and Co

F-star Biotechnology Ltd

Fountain Biopharma Inc

GigaGen Inc

Immutep Ltd

Incyte Corp

Innovent Biologics Inc

MacroGenics Inc

Merck & Co Inc

Novartis AG

Regeneron Pharmaceuticals Inc

Stcube Inc

Symphogen A/S

TESARO Inc

Xencor Inc

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
(nivolumab + relatlimab) - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
AM-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-754111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit PDL1 and LAG3 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemiplimab + REGN-3767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

IBI-323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-2385 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAG-525 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGD-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-4280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit LAG3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relatlimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STT-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-033 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-075 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-22841 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones

Featured News & Press Releases

Oct 01, 2018: TESARO announces data presentation on solid tumors drug candidate TSR-033 at the SITC 2018 Annual Meeting

Sep 17, 2018: Agenus receives milestone payment from Incyte

Sep 03, 2018: Immutep: Progress Towards Clinical Development of IMP761 - a LAG-3 Agonist Antibody

Jul 24, 2018: F-star announces the Achievement of a Clinical Milestone in its Immunology Collaboration with Merck

Jul 10, 2018: Symphogen opens investigational new drug application for antibody

candidate Sym022

May 21, 2018: F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody

Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting

Apr 03, 2018: Immutep Provides Update On IMP761

Mar 06, 2018: Immutep Announces United States Patent Grant for IMP701 Antibody

Nov 10, 2017: MacroGenics Announces Poster Presentations on MGD013 at 32nd Annual SITC Meeting 2017

Sep 05, 2017: MacroGenics Provides Update on its DART candidate MGD013

Jul 16, 2017: Prima BioMed Announces Second Milestone Payment for IMP701 Program

Jun 04, 2017: Merck Strengthens Immuno-Oncology Portfolio through Expansion of F-star Collaboration including LAG-3/PD-L1 Bispecific Antibody

Jun 03, 2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy

May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Avacta Life Sciences Ltd, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Crescendo Biologics Ltd, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by F-star Biotechnology Ltd, H2 2018
Pipeline by Fountain Biopharma Inc, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Immutep Ltd, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by MacroGenics Inc, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Stcube Inc, H2 2018
Pipeline by Symphogen A/S, H2 2018
Pipeline by TESARO Inc, H2 2018
Pipeline by Xencor Inc, H2 2018
Dormant Projects, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Avacta Life Sciences Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Crescendo Biologics Ltd

Eli Lilly and Co

F-star Biotechnology Ltd

Fountain Biopharma Inc

GigaGen Inc

Immutep Ltd

Incyte Corp

Innovent Biologics Inc

MacroGenics Inc

Merck & Co Inc

Novartis AG

Regeneron Pharmaceuticals Inc

Stcube Inc

Symphogen A/S

TESARO Inc

Xencor Inc

I would like to order

Product name: Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/LD10DF492FDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LD10DF492FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

